Artiva Biotherapeutics, Inc. (ARTV)

NGM – Real vaqt narxi. Valyuta: USD

11.60

-0.17 (-1.49%)

Bozor ochiq: Aug 12, 2026, 1:53 PM EDT

11.61

-0.17 (-1.44%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®'s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient administration U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory rheumatoid arthritis (RA) Initiating Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients in the second half of 2026 Strong balance sheet with cash, cash equivalents and investments of $349.4 million as of June 30, 2026, expected to fund operations into 2029 SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced financial results for the second quarter ended June 30, 2026, and highlighted recent progress. “The second quarter was transformative for Artiva.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Artiva Biotherapeutics, Inc. (ARTV)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Videolar

No Data

Press-relizlar

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Videolar

No Data

Press-relizlar

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Search stocks

Artiva Biotherapeutics, Inc. (ARTV)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Videolar

No Data

Press-relizlar

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Videolar

No Data

Press-relizlar

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights